Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia

被引：10
|
作者：
Kurosawa, Motohiro [1 ]
机构：
[1] Sutoh Hosp, Dept Allergy & Resp Med, 3532-5 Annaka, Gunma 3790116, Japan
来源：
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY | 2020年 / 30卷 / 02期
关键词：
Benralizumab; Chronic eosinophilic pneumonia; Anti-interleukin; 5; antibody; Mepolizumab;
D O I：
10.18176/jiaci.0468
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：154 / 155
页数：2
相关论文
共 50 条
  • [21] Long-Term Outcome And Prognostic Factors Of Chronic Eosinophilic Pneumonia: Fujiyama Cohort Study
    Suzuki, Y.
    Imokawa, S.
    Toyoshima, M.
    Yokomura, K.
    Nakamura, H.
    Kuroishi, S.
    Koshimizu, N.
    Ohyama, Y.
    Furuhashi, K.
    Fujisawa, T.
    Enomoto, N.
    Inui, N.
    Nakamura, Y.
    Yamada, T.
    Shirai, T.
    Masuda, M.
    Hayakawa, H.
    Suda, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [22] Targeting eosinophils in chronic eosinophilic pneumonia: new therapeutic perspectives for long-term control
    Cisternino, C.
    Steffanina, A.
    Scarano, P.
    Lo Muzio, G.
    Calo, O.
    Sanna, A.
    De Filippis, F.
    Leporini, M. T.
    Palange, P.
    Graziani, E.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [23] The clinical question of mepolizumab in the long-term treatment of idiopathic chronic eosinophilic pneumonia; how long should we use mepolizumab?
    Hamakawa, Masamitsu
    Arita, Machiko
    Takahashi, Hiroshi
    Amano, Akihiko
    Hamao, Nobuyoshi
    Tanaka, Ayaka
    Ito, Akihiro
    Ishida, Tadashi
    RESPIRATORY MEDICINE CASE REPORTS, 2024, 52
  • [24] Anti-interleukin 5 Therapy for Eosinophilic Asthma: a Meta-analysis of Randomized Clinical Trials
    Wang, Fa-Ping
    Xiong, Xiao-Feng
    Liu, Ting
    Li, Su-Yun
    Cheng, De-Yun
    Mao, Hui
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2018, 54 (02) : 318 - 330
  • [25] Anti-interleukin 5 Therapy for Eosinophilic Asthma: a Meta-analysis of Randomized Clinical Trials
    Fa-Ping Wang
    Xiao-Feng Xiong
    Ting Liu
    Su-Yun Li
    De-Yun Cheng
    Hui Mao
    Clinical Reviews in Allergy & Immunology, 2018, 54 : 318 - 330
  • [26] Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
    Castro, Mario
    Bacharier, Leonard B.
    LANCET, 2016, 388 (10056): : 2059 - 2060
  • [27] Long-term safety and efficacy of anti-interleukin 6 receptor antibody (MRA) in patients with rheumatoid arthritis.
    Nishimoto, N
    Yoshizaki, K
    Miyasaka, N
    Yamamoto, K
    Kawai, S
    Takeuchi, T
    Hashimoto, J
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S126 - S126
  • [28] Humanized anti-interleukin 6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia
    Kunitomi, A
    Konaka, Y
    Yagita, M
    Nishimoto, N
    Kishimoto, T
    Takatsuki, K
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 80 (03) : 246 - 249
  • [29] Humanized Anti-Interleukin 6 Receptor Antibody Induced Long-term Remission in a Patient with Life-Threatening Refractory Autoimmune Hemolytic Anemia
    Akane Kunitomi
    Yoshiteru Konaka
    Masato Yagita
    Kiyoshi Takatsuki
    Norihiro Nishimoto
    Tadamitsu Kishimoto
    International Journal of Hematology, 2004, 80 : 246 - 249
  • [30] Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series
    Tashiro, Hiroki
    Takahashi, Koichiro
    Kurihara, Yuki
    Sadamatsu, Hironori
    Kuwahara, Yuki
    Kimura, Shinya
    Sueoka-Aragane, Naoko
    JOURNAL OF ASTHMA AND ALLERGY, 2022, 15 : 169 - 177
12345